文献速递泌尿男性生殖肿瘤

基于RNA的数字循环肿瘤细胞特征可预测前列腺癌药物反应和早期播散

An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.
PubMed 文献 · Cancer Discov · 2018-01-04

该研究建立了一种基于微流控富集结合数字定量前列腺来源转录本的循环肿瘤细胞(CTC)分析策略。在27例转移性去势抵抗性前列腺癌患者中,治疗前CTCM评分升高与总生存差(HR=6.0;P=0.01)和影像学无进展生存短(HR=3.2;P=0.046)相关。在34例局限性前列腺癌患者中,术前CTCL评分升高可预测精囊和/或淋巴结的微转移(P<0.001)。

要点

  • 治疗前CTCM评分高提示转移性去势抵抗性前列腺癌患者阿比特龙治疗预后差。
  • CTC中HOXB13表达可识别生存期≤12个月的患者,部分共表达ARV7。
  • 术前CTCL评分高预测局限性前列腺癌精囊和/或淋巴结微转移。

核心结论

  • 基于CTC特异性转录本的数字定量可实现无创监测,可能指导转移性和局限性前列腺癌的治疗选择。

研究设计与样本

  • 前瞻性研究,纳入27例接受一线阿比特龙治疗的转移性去势抵抗性前列腺癌患者。
  • 另纳入34例局限性前列腺癌患者作为第二队列。
  • 采用微流控细胞富集后数字定量前列腺来源转录本。

主要发现

  • 治疗前CTCM评分升高与总生存差相关(HR=6.0;P=0.01)。
  • 治疗前CTCM评分升高与影像学无进展生存短相关(HR=3.2;P=0.046)。
  • CTC中HOXB13表达识别6/6例生存期≤12个月的患者,部分表达ARV7剪接变体。
  • 术前CTCL评分升高预测精囊和/或淋巴结微转移(P<0.001)。

临床怎么用

  • 治疗前检测CTCM评分可能帮助识别阿比特龙治疗高风险患者。
  • 术前检测CTCL评分可能辅助评估局限性前列腺癌的微转移风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blood-based biomarkers are critical in metastatic prostate cancer, where characteristic bone metastases are not readily sampled, and they may enable risk stratification in localized disease. We established a sensitive and high-throughput strategy for analyzing prostate circulating tumor cells (CTC) using microfluidic cell enrichment followed by digital quantitation of prostate-derived transcripts. In a prospective study of 27 patients with metastatic castration-resistant prostate cancer treated with first-line abiraterone, pretreatment elevation of the digital CTCM score identifies a high-risk population with poor overall survival (HR = 6.0; P = 0.01) and short radiographic progression-free survival (HR = 3.2; P = 0.046). Expression of HOXB13 in CTCs identifies 6 of 6 patients with ≤12-month survival, with a subset also expressing the ARV7 splice variant. In a second cohort of 34 men with localized prostate cancer, an elevated preoperative CTCL score predicts microscopic dissemination to seminal vesicles and/or lymph nodes (P < 0.001). Thus, digital quantitation of CTC-specific transcripts enables noninvasive monitoring that may guide treatment selection in both metastatic and localized prostate cancer.Significance: There is an unmet need for biomarkers to guide prostate cancer therapies, for curative treatment of localized cancer and for application of molecularly targeted agents in metastatic disease. Digital quantitation of prostate CTC-derived transcripts in blood specimens is predictive of abiraterone response in metastatic cancer and of early dissemination in localized cancer. Cancer Discov; 8(3); 288-303. ©2018 AACR.See related commentary by Heitzer and Speicher, p. 269This article is highlighted in the In This Issue feature, p. 253.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Miyamoto DT, Lee RJ, Kalinich M, et al. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discov. 2018. PMID: 29301747. doi:10.1158/2159-8290.CD-16-1406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。